272. Fibrodysplasia ossificans progressiva Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 39 / Drugs : 38 - (DrugBank : 7) / Drug target genes : 27 - Drug target pathways : 95
Fibrodysplasia ossificans progressiva and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
ID | Diseases (Sorted by drug repositionability) |
---|---|
272 | Fibrodysplasia ossificans progressiva |
6 | Parkinson disease |
140 | Dorabe syndrome |
13 | Multiple sclerosis/Neuromyelitis optica |
144 | Lennox-Gastaut syndrome |
193 | Prader-Willi syndrome |
298 | Hereditary pancreatitis |
70 | Spinal stenosis |
156 | Rett syndrome |
97 | Ulcerative colitis |
152 | PCDH19 related syndrome |
96 | Crohn disease |
201 | Angelman syndrome |
205 | Fragile X syndrome related disease |
145 | West syndrome |
22 | Moyamoya disease |
155 | Acquired aphasia with convulsive disorder |
2 | Amyotrophic lateral sclerosis |
231 | Alpha-1-antitrypsin deficiency |
158 | Tuberous sclerosis |
8 | Huntington disease |
34 | Neurofibromatosis |
98 | Eosinophilic gastrointestinal disease |
296 | Biliary atresia |
18 | Spinocerebellar degeneration |
21 | Mitochondrial disease |
36 | Epidermolysis bullosa |
3 | Spinal muscular atrophy |
206 | Fragile X syndrome |
46 | Malignant rheumatoid arthritis |
17 | Multiple system atrophy |
75 | Cushing disease |
5 | Progressive supranuclear palsy |
84 | Sarcoidosis |
58 | Hypertrophic cardiomyopathy |
67 | Polycystic kidney disease |
167 | Marfan syndrome |
81 | Congenital adrenal hyperplasia |
51 | Scleroderma |
86 | Pulmonary arterial hypertension |